HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) with a maintained price target of $16.
May 08, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics maintains a Buy rating and a $16 price target from HC Wainwright & Co., indicating a positive outlook from the analyst.
The reiteration of a Buy rating and a maintained price target of $16 by HC Wainwright & Co. suggests a strong belief in the potential of Esperion Therapeutics. This positive analyst outlook can influence investor sentiment and potentially lead to a short-term increase in ESPR's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100